Docking studies on isoform-specific inhibition of phosphoinositide-3- kinases

Journal of Chemical Information and Modeling

Volumn 50, Issue 10, 2010, Pages 1887-1898

  Sabbah, Dima A ^a   Vennerstrom, Jonathan L ^a   Zhong, Haizhen ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; MOLECULAR DYNAMICS;

CATALYTIC DOMAINS; COMPUTATIONAL DATA; CONFORMATIONAL DIFFERENCES; HYDROPHOBIC DOMAINS; MOLECULAR DYNAMICS SIMULATIONS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDES; PROTEIN FLEXIBILITY;

LIGANDS;

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MOLECULAR DYNAMICS; MUTATION; NEOPLASM; PROTEIN BINDING; PROTEIN CONFORMATION;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ISOFORMS;

EID: 77958527569     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci1002679     Document Type: Article

References (43)

1. Bader, A. G.; Kang, S.; Zhao, L.; Vogt, P. K. Oncogenic PI3K deregulates transcription and translation Nat. Rev. Cancer 2005, 5, 921-929
2. Chang, H. W.; Aoki, M.; Fruman, D.; Auger, K. R.; Bellacosa, A.; Tsichlis, P. N.; Cantley, L. C.; Roberts, T. M.; Vogt, P. K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-Kinase Science 1997, 276, 1848-1850
3. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timm, J.; Waterfield, M. D. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis and cancer Annu. Rev. Cell. Dev. Biol. 2001, 17, 615-675
4. Vanhaesebroeck, B.; Waterfield, M. D. Signaling by distinct classes of phosphoinositide 3-kinases Exp. Cell Res. 1999, 253, 239-254
5. Huang, C. H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations Science 2007, 318, 1744-1748
6. Perrone, F.; Lampis, A.; Orsenigo, M.; Di Bartolomeo, M.; Gevorgyan, A.; Losa, M.; Frattini, M.; Riva, C.; Andreola, S.; Bajetta, E.; Bertario, L.; Leo, E.; Pierotti, M. A.; Pilotti, S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann. Oncol. 2009, 20, 84-90
7. She, Q. B.; Solit, D.; Basso, A.; Moasser, M. M. Resistance to gefitinib (ZD1839, Iressa) in PTEN null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling Clin. Cancer Res. 2003, 9, 4340-4346
8. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554-554
9. Liu, I.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
10. Carson, J. D.; Aller, G. V.; Lehr, R.; Sinnamon, R. H.; Kirkpartick, R. B.; Auger, K. R.; Dhanak, D.; Copeland, R. A.; Gontarek, R. R.; Tummino, P. J.; Luo, L. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase Biochem. J. 2008, 409, 519-524
11. Zask, A.; Kaplan, J.; Toral-Barza, L.; Hollander, I.; Young, M.; Tischler, M.; Gaydos, C.; Cinque, M.; Lucas, J.; Yu, K. Synthesis and structure-activity relationships of ring-opened 17 hydroxywortmannins: Potent phosphinositide 3-kinase inhibitors with improved properties and anticancer efficacy J. Med. Chem. 2008, 51, 1319-1323
12. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. 2006, 14, 6847-6858
13. Zvelebil, M. J.; Waterfield, M. D.; Shuttleworth, S. J. Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors Arch. Biochem. Biophys. 2008, 477, 404-410
14. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; García-Echeverría, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 2008, 7, 1851-1863
15. Marion, F.; Williams, D. E.; Patrick, B. O.; Hollander, I.; Mallon, R.; Kim, S. C.; Roll, D. M.; Feldberg, L.; Soest, R. V.; Andersen, R. J. Liphagal, a selective inhibitor of PI3 kinase α isolated from the sponge Aka coralliphaga: Structure elucidation and biomimetic synthesis Org. Lett. 2006, 8, 321-324
16. -Exelixis and Nektar Therapeutics IDrugs 2010, 13 (3) 139-141
17. Markman, B.; LuRusso, P. M.; Patnaik, A.; Heath, E.; Laird, A. D.; van Leeuwen, B.; Papadopoulos, K. P.; Baselga, J. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL-765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors Eur. J. Cancer Suppl. 2008, 6 (12) 68-69
18. Hayakawa, M.; Kawaguchi, K.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohata, M.; Tsukamoto, S.; Reynaud, F.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazole[1,2-a]pyridines as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. 2007, 15, 5837-5844 (Pubitemid 47043472)
19. Kendall, J. D.; Rewcastle, G. W.; Frederick, R.; Mawson, C.; Denny, W. A.; Marshall, E. S.; Baguley, B. C.; Chaussade, C.; Jackson, S. P.; Shepherd, P. R. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors Bioorg. Med. Chem. 2007, 15, 7677-7687
20. Frédérick, R.; Denny, W. A. Phosphoinositide-3-kinases (PI3Ks): Combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110α J. Chem. Inf. Model. 2008, 48, 629-638
21. Li, Y.; Wang, Y.; Zhang, F. Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors J. Mol. Model 2010, 9, 1449-1460
22. Zask, A.; Verheijen, J. C.; Curran, K.; Kaplan, J.; Richard, D. J.; Nowak, P.; Malwitz, D. J.; Brooijmans, N.; Bard, J.; Svenson, K.; Lucas, J.; Toral-Barza, L.; Zhang, W. G.; Hollander, I.; Gibbons, J. J.; Abraham, R. T.; Ayral-Kaloustian, S.; Mansour, T. S.; Yu, K. ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines J. Med. Chem. 2009, 52, 5013-5016
23. Mandelker, D.; Gabelli, S.; Schmidt-kittler, O.; Zhu, J.; Cheong, I.; Huang, C. H.; Kinzler, K.; Vogelstein, B.; Amzel, M. A frequent kinase domain mutation that changes the interaction between PI3K α and the membrane Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16996-17001
24. Holm, L.; Park, J. DaliLite workbench for protein structure comparison Bioinformatics 2000, 16, 566-567 available online at http://www.ebi.ac.uk/Tools/ dalilite/ index.html (accessed Jan 28, 2010)
25. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephen, L.; Hawkins, P. T.; Whymann, M. P.; Williams, R. L. Structural determinations of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine Mol. Cell 2000, 6, 909-919
26. The Molecular Operating Environment (MOE); Chemical Computing Group Inc.: Montreal, Quebec, Canada, 2009.
27. Thoden, J. B.; Miran, S. G.; Phillips, J. C.; Howard, A. J.; Raushel, F. M.; Holden, H. M. Carbomoyl phosphate synthetase: Caught in the act of glutamine hydrolysis Biochemistry 1998, 37, 8825-8831
28. Sheng, Y.; Laister, R.; Lemak, A.; Wu, B.; Tai, E.; Duan, S.; Lukin, J.; Sunnerhagen, M.; Srisailam, S.; Karra, M.; Benchimol, S.; Arrowsmith, C. H. Molecular basis of Pirh2-mediated p53 ubiquitylation Nat. Struct. Mol. Biol. 2008, 15, 1334-1342
29. Wu, J. W.; Cocina, A. E.; Chai, J.; Hay, B. A.; Shi, Y. Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides Mol. Cell 2001, 8, 95-104
30. Milburn, M. V.; Hassell, A. M.; Lambert, M. H.; Jordan, S. R.; Proudfoot, A. E.; Graber, P.; Wells, T. N. A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5 Nature 1993, 363, 172-176
31. Protein Preparation Wizard, Maestro, MacroModel, and Glide; Schrödinger, LLC: Portland, OR, 2009.
32. Pineda-Lucena, A.; Liao, J.; Wu, B.; Yee, A.; Cort, J. R.; Kennedy, M. A.; Edwards, A. M.; Arrowsmith, C. H. NMR Structure of the Hypothetical Protein Encoded by the YjbJ gene from Escherichia coli Proteins: Struct. Funct. Bioinf. 2002, 47, 572-574
33. NCI Open Database Compounds, release 3; National Cancer Institute, National Institutes of Health: Bethseda, MD, Sep 2003). Available online at: http://cactus.nci.nih.gov/download/nci (accessed Aug 18, 2008).
34. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
35. Zhong, H. Z.; Carlson, H. A. Computational studies and peptidomimetic design for the human p53-MDM2 complex Proteins: Struct. Funct. Bioinf. 2005, 58, 222-234
36. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
37. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N ·log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092
38. Case, D. A.; Darden, D. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Crowley, M.; Walker, R. C.; Zhang, W.; Merz, K. M.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossvàry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Mongan, J.; Hornak, V.; Kollman, P. A. AMBER 10; University of California: San Francisco, CA, 2008.
39. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. L. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins: Struct. Funct. Bioinf. 2006, 65, 712-725
40. Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. A.; Johnson, D. W.; Rutherford, P. G.; Schultz, R. M.; Worzalla, J. F.; Vlahos, C. J. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs J. Med. Chem. 1996, 39, 1106-1111
41. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Workman, P.; Waterfield, M.; Parker, P. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2438-2442 (Pubitemid 46507793)
42. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C.-M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin ACS Med. Chem. Lett. 2010, 1, 39-43
43. Han, M.; Zhang, J. Z. H. Class I phosphor-inositide-3-kinase (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation J. Chem. Inf. Model. 2010, 50, 136-145